We use cookies to give you the best possible experience. If you continue, we’ll assume you are happy to receive the cookies we place. Privacy and cookies information.
News
-
Annual Inpatient Survey ranks The Royal Marsden as one of the best places in England to receive care
25 June 2019
The Royal Marsden is one of the best places in England to receive care, according to recent results published by the Care Quality Commission.
Read more -
Break through immunotherapy drug trial at The Royal Marsden
24 June 2019
The Royal Marsden is leading one of the world’s first immunotherapy trials for colorectal cancer that has been removed by surgery.
Read more -
Myeloma- early diagnosis
24 June 2019
50 year old Fin Monahan benefited from a whole body MRI scan at The Royal Marsden which picked up traces that his cancer had returned after a five year remission.
Read more -
Statement in support of our children's centre team
21 June 2019
The Royal Marsden has recently featured in press stories with regard to the quality and safety of our paediatrics service.
Read more -
In our DNA
21 June 2019
While whole-genome profiling for childhood cancers remains the ultimate goal, young patients at The Royal Marsden are already benefiting from genetic tests
Read more -
The Royal Marsden awarded accreditation as a London Healthy Workplace
20 June 2019
The Royal Marsden has successfully satisfied the criteria for the Foundation level of London Healthy Workplace Award
Read more -
Pioneering software set to improve NHS imaging services across north west London
4 June 2019
Read more -
Friends of The Royal Marsden, Chelsea receives the Queen’s Award for Voluntary Service
3 June 2019
The Friends of The Royal Marsden, Chelsea have been honoured with the Queen’s Award for Voluntary Service, the highest award a voluntary group can receive in the UK.
Read more -
Retroperitoneal sarcoma: The search for the best treatment
3 June 2019
Retroperitoneal sarcoma is a rare malignancy where tumours develop in the tissue at the back of the abdomen next to the kidneys. It is not a single disease, but consists of a few different, well-defined subtypes of sarcomas. Occurring in less than one in every 100,000 people, it is hard to manage, with difficulties typically encountered when carrying out research - associated with the small population sizes.
Read more -
Clinical calculator could spare breast cancer patients five years of unnecessary hormone therapy
30 May 2019
New research confirms that an algorithm, called CTS5, accurately identifies patients who are at low risk of their breast cancer returning at a later stage. In doing so it means some patients may need to take hormone therapy for five years, rather than 10, something that researchers say could have a huge impact both psychologically and physically.
Read more